Asterias Biotherapeutics Company Profile (NYSEMKT:AST)

About Asterias Biotherapeutics (NYSEMKT:AST)

Asterias Biotherapeutics logoAsterias Biotherapeutics, Inc. is a biotechnology company. The Company is engaged in developing and commercializing therapies in the fields of cell therapy and regenerative medicine. The Company has over two technology platforms. The first is an immunotherapy platform to teach cancer patients' immune systems to attack their tumors. The second is pluripotent stem cell platform. Pluripotent cells are a type of stem cell capable of becoming all of the cell types in the human body. From its immunotherapy platform, the Company is developing over two programs. AST-VAC1 (telomerase loaded, autologous dendritic cells), which allows patient's own cells to recognize and fight cancer cells in acute myelogenous leukemia (AML). Together with Cancer Research United Kingdom (CRUK), it is developing AST-VAC2 (telomerase loaded, -allogeneic dendritic cells), -derived from pluripotent stem cells. From its pluripotent stem cell platform, it is developing AST-OPC1, oligodendrocyte progenitor cells.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: N/A
  • Symbol: NYSEMKT:AST
  • CUSIP: N/A
  • Web: asteriasbiotherapeutics.com
Capitalization:
  • Market Cap: $137.44 million
  • Outstanding Shares: 49,978,000
Average Prices:
  • 50 Day Moving Avg: $3.23
  • 200 Day Moving Avg: $3.31
  • 52 Week Range: $2.60 - $5.80
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.74
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $6.15 million
  • Price / Sales: 22.35
  • Book Value: $0.74 per share
  • Price / Book: 3.72
Profitability:
  • EBITDA: ($29,790,000.00)
  • Net Margins: -2,762.03%
  • Return on Equity: -86.25%
  • Return on Assets: -66.19%
Misc:
  • Average Volume: 166,749 shs.
  • Beta: 1.58
  • Short Ratio: 20.53
 

Frequently Asked Questions for Asterias Biotherapeutics (NYSEMKT:AST)

What is Asterias Biotherapeutics' stock symbol?

Asterias Biotherapeutics trades on the New York Stock Exchange (NYSE)MKT under the ticker symbol "AST."

How were Asterias Biotherapeutics' earnings last quarter?

Asterias Biotherapeutics Inc (NYSEMKT:AST) announced its quarterly earnings results on Monday, August, 15th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.19) by $0.07. The business earned $1.53 million during the quarter, compared to the consensus estimate of $1.14 million. Asterias Biotherapeutics had a negative return on equity of 86.25% and a negative net margin of 2,762.03%. View Asterias Biotherapeutics' Earnings History.

Where is Asterias Biotherapeutics' stock going? Where will Asterias Biotherapeutics' stock price be in 2017?

2 brokers have issued 12 month price objectives for Asterias Biotherapeutics' stock. Their predictions range from $10.00 to $10.00. On average, they anticipate Asterias Biotherapeutics' share price to reach $10.00 in the next year. View Analyst Ratings for Asterias Biotherapeutics.

Who are some of Asterias Biotherapeutics' key competitors?

Who are Asterias Biotherapeutics' key executives?

Asterias Biotherapeutics' management team includes the folowing people:

  • Don M. Bailey, Chairman of the Board
  • Michael H. Mulroy, President, Chief Executive Officer, Director
  • Ryan Daniel Chavez, Chief Financial Officer, General Counsel
  • Katharine E. Spink Ph.D., Chief Operating Officer, Executive Vice President
  • Casey C. Case Ph.D., Senior Vice President - Research and Nonclinical Development
  • Jane S. Lebkowski Ph.D., Chief Scientific Officer
  • Edward D. Wirth III, Chief Medical Officer
  • Stephen L. Cartt, Director
  • Alfred D. Kingsley, Director
  • Aditya P. Mohanty, Director

How do I buy Asterias Biotherapeutics stock?

Shares of Asterias Biotherapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Asterias Biotherapeutics' stock price today?

One share of Asterias Biotherapeutics stock can currently be purchased for approximately $2.75.


MarketBeat Community Rating for Asterias Biotherapeutics (NYSEMKT AST)
Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  100 (Vote Outperform)
Underperform Votes:  100 (Vote Underperform)
Total Votes:  200
MarketBeat's community ratings are surveys of what our community members think about Asterias Biotherapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Asterias Biotherapeutics (NYSEMKT:AST) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $10.00
Consensus Price Target History for Asterias Biotherapeutics (NYSEMKT:AST)
Price Target History for Asterias Biotherapeutics (NYSEMKT:AST)
Analysts' Ratings History for Asterias Biotherapeutics (NYSEMKT:AST)
Show:
DateFirmActionRatingPrice TargetDetails
8/16/2017HC WainwrightReiterated RatingBuyView Rating Details
3/7/2017FBR & CoBoost Price TargetOutperform$6.00 -> $10.00View Rating Details
5/23/2016Chardan CapitalInitiated CoverageBuy$5.50View Rating Details
5/17/2016Rodman & RenshawReiterated RatingBuy$10.00View Rating Details
(Data available from 10/23/2015 forward)

Earnings

Earnings History for Asterias Biotherapeutics (NYSEMKT:AST)
Earnings by Quarter for Asterias Biotherapeutics (NYSEMKT:AST)
Earnings History by Quarter for Asterias Biotherapeutics (NYSEMKT AST)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/14/2016Q316($0.17)($0.24)$1.50 million$2.10 millionViewN/AView Earnings Details
8/15/2016Q216($0.19)($0.12)$1.14 million$1.53 millionViewListenView Earnings Details
5/16/2016Q116($0.14)($0.27)$1.60 millionViewListenView Earnings Details
3/29/2016Q415($0.13)($0.13)$1.07 millionViewListenView Earnings Details
11/9/2015Q315($0.11)($0.06)$1.40 millionViewN/AView Earnings Details
8/10/2015Q215($0.11)($0.10)ViewListenView Earnings Details
5/7/2015($0.13)($0.14)ViewN/AView Earnings Details
3/10/2015($0.13)($0.11)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Asterias Biotherapeutics (NYSEMKT:AST)
Current Year EPS Consensus Estimate: $-0.61 EPS
Next Year EPS Consensus Estimate: $-0.58 EPS

Dividends

Dividend History for Asterias Biotherapeutics (NYSEMKT:AST)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Asterias Biotherapeutics (NYSEMKT:AST)
Insider Trades by Quarter for Asterias Biotherapeutics (NYSEMKT:AST)
Institutional Ownership by Quarter for Asterias Biotherapeutics (NYSEMKT:AST)
Insider Trades by Quarter for Asterias Biotherapeutics (NYSEMKT:AST)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/9/2017Edward WirthInsiderSell3,415$4.60$15,709.00View SEC Filing  
1/9/2017Katharine E SpinkCOOSell4,781$4.60$21,992.60View SEC Filing  
10/6/2016Edward WirthInsiderSell3,415$4.12$14,069.80View SEC Filing  
10/6/2016Katharine E. SpinkCOOSell4,781$4.11$19,649.91View SEC Filing  
9/9/2016Edward WirthInsiderSell14,760$3.52$51,955.20View SEC Filing  
9/9/2016Katharine E. SpinkCOOSell19,336$3.52$68,062.72View SEC Filing  
6/30/2016Stephen Lahue CarttCEOBuy10,000$2.40$24,000.00View SEC Filing  
6/29/2016Richard T LebuhnDirectorBuy5,000$2.38$11,900.00View SEC Filing  
6/10/2016Stephen Lahue CarttCEOBuy50,000$2.93$146,500.00View SEC Filing  
6/9/2016Alfred D KingsleyDirectorBuy4,000$2.93$11,720.00View SEC Filing  
5/13/2016Natale S RicciardiDirectorBuy14,706$3.39$49,853.34View SEC Filing  
9/15/2015Edward WirthinsiderSell2,880$6.00$17,280.00View SEC Filing  
9/15/2015Katharine E. SpinkCOOSell3,760$6.00$22,560.00View SEC Filing  
6/25/2015Andrew ArnoDirectorBuy5,000$4.32$21,600.00View SEC Filing  
2/9/2015Pedro LichtingerCEOBuy128,205$3.90$499,999.50View SEC Filing  
10/1/2014Scarsdale Equities LlcMajor ShareholderBuy60,000$5.93$355,800.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Asterias Biotherapeutics (NYSEMKT:AST)
Latest Headlines for Asterias Biotherapeutics (NYSEMKT:AST)
Source:
Loading headlines, please wait.

Social

Chart

Asterias Biotherapeutics (AST) Chart for Monday, October, 23, 2017

This page was last updated on 10/23/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.